Literature DB >> 6305538

Pro-opiocortin related peptides in human pituitary and ectopic ACTH secreting tumours.

S J Ratter, G Gillies, J Hope, A C Hale, A Grossman, R Gaillard, D Cook, C R Edwards, L H Rees.   

Abstract

Basal and stimulated secretion of N-terminal pro-opiocortin (Pro-gamma-MSH), ACTH and LPH from seven pituitary and three ectopic ACTH secreting tumours have been studied in vitro using a perfused isolated cell system. The peptides were shown to be released concomitantly and in equimolar amounts. The pituitary tumours responded to stimulation with rat stalk median eminence extracts (SME) and synthetic AVP. However, peptide release from the ectopic tumours, although pulsatile, remained autonomous. Prior to surgery, gel-chromatographic profiles of plasma immunoreactive ACTH showed only one peak, which eluted in the position of 1-39 ACTH, in patients with the pituitary tumours, but there was a second peak of large molecular weight ACTH present in the plasma from those with the ectopic ACTH syndrome. This second form of ACTH could not be detected in any of the tumour cell column effluents. An eighth pituitary tumour was atypical, in its unusually large size, clinically aggressive nature and spectrum of peptide release. Although peptide release in response to stimulation with SME was similar to that observed with the other pituitary tumours, the chromatography of the plasma ACTH resembled the ectopic plasma pattern, showing two peaks of immunoreactivity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305538     DOI: 10.1111/j.1365-2265.1983.tb03205.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

1.  Characterisation of ACTH related peptides in ectopic Cushing's syndrome.

Authors:  Robert L Oliver; Julian R E Davis; Anne White
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

2.  Evidence for ectopic ACTH production years after bilateral adrenalectomy for Cushing's syndrome: in vivo and in vitro studies.

Authors:  M Boscaro; G Merola; N Sonino; A M Menegus; F Sartori; F Mantero
Journal:  J Endocrinol Invest       Date:  1985-10       Impact factor: 4.256

3.  Immunocytochemical study of 18 tumours causing ectopic Cushing's syndrome.

Authors:  P J Coates; I Doniach; T A Howlett; L H Rees; G M Besser
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

Review 4.  POMC: The Physiological Power of Hormone Processing.

Authors:  Erika Harno; Thanuja Gali Ramamoorthy; Anthony P Coll; Anne White
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

5.  Cushing's syndrome and bronchial carcinoid tumour.

Authors:  P S Ward; M G Mott; J Smith; M Hartog
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

6.  Limited clinical usefulness of plasma corticotropin-releasing hormone, adrenocorticotropin and beta-endorphin measurements as markers of lung cancer.

Authors:  A E Calogero; G Minacapilli; A M Nicolosi; M L Moncada; A Mistretta; S F Latteri; P Polosa; R D'Agata
Journal:  J Endocrinol Invest       Date:  1992-09       Impact factor: 4.256

7.  Clinical utility of plasma POMC and AgRP measurements in the differential diagnosis of ACTH-dependent Cushing's syndrome.

Authors:  Gabrielle Page-Wilson; Pamela U Freda; Thomas P Jacobs; Alexander G Khandji; Jeffrey N Bruce; Sandra T Foo; Kana Meece; Anne White; Sharon L Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  2014-07-11       Impact factor: 5.958

8.  High Molecular Weight ACTH-Precursor Presence in a Metastatic Pancreatic Neuroendocrine Tumor Causing Severe Ectopic Cushing's Syndrome: A Case Report.

Authors:  Roopa Mehta; César Ernesto Lam-Chung; José Miguel Hinojosa-Amaya; Paola Roldán-Sarmiento; Maria Fernanda Guillen-Placencia; Gerladine Villanueva-Rodriguez; Oscar Alfredo Juarez-Leon; Jefsi Leon-Domínguez; Mariana Grajales-Gómez; Jose Luis Ventura-Gallegos; Andrés León-Suárez; Francisco J Gómez-Pérez; Daniel Cuevas-Ramos
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-13       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.